WO2001055300A3 - Nucleic acids, proteins, and antibodies - Google Patents

Nucleic acids, proteins, and antibodies Download PDF

Info

Publication number
WO2001055300A3
WO2001055300A3 PCT/US2001/001238 US0101238W WO0155300A3 WO 2001055300 A3 WO2001055300 A3 WO 2001055300A3 US 0101238 W US0101238 W US 0101238W WO 0155300 A3 WO0155300 A3 WO 0155300A3
Authority
WO
WIPO (PCT)
Prior art keywords
lung cancer
polypeptides
polynucleotides
methods
further relates
Prior art date
Application number
PCT/US2001/001238
Other languages
French (fr)
Other versions
WO2001055300A8 (en
WO2001055300A2 (en
Inventor
Craig A Rosen
Steven C Barash
Steven M Ruben
Original Assignee
Human Genome Sciences Inc
Craig A Rosen
Steven C Barash
Steven M Ruben
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Craig A Rosen, Steven C Barash, Steven M Ruben filed Critical Human Genome Sciences Inc
Priority to AU2001237943A priority Critical patent/AU2001237943A1/en
Priority to EP01910325A priority patent/EP1254219A2/en
Publication of WO2001055300A2 publication Critical patent/WO2001055300A2/en
Publication of WO2001055300A8 publication Critical patent/WO2001055300A8/en
Publication of WO2001055300A3 publication Critical patent/WO2001055300A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to novel lung cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as 'lung cancer antigens', and the use of such lung cancer antigens for detecting disorders of the lung, particularly the presence of lung cancer and lung cancer metastases. More specifically, isolated lung cancer associated nucleic acid molecules are provided encoding novel lung cancer associated polypeptides. Novel lung cancer polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human lung cancer associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the lung, including lung cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.
PCT/US2001/001238 2000-01-31 2001-01-17 Nucleic acids, proteins, and antibodies WO2001055300A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001237943A AU2001237943A1 (en) 2000-01-31 2001-01-17 Nucleic acids, proteins, and antibodies
EP01910325A EP1254219A2 (en) 2000-01-31 2001-01-17 Nucleic acids, proteins, and antibodies

Applications Claiming Priority (235)

Application Number Priority Date Filing Date Title
US17906500P 2000-01-31 2000-01-31
US60/179,065 2000-01-31
US18062800P 2000-02-04 2000-02-04
US60/180,628 2000-02-04
US18466400P 2000-02-24 2000-02-24
US60/184,664 2000-02-24
US18635000P 2000-03-02 2000-03-02
US60/186,350 2000-03-02
US18987400P 2000-03-16 2000-03-16
US60/189,874 2000-03-16
US19007600P 2000-03-17 2000-03-17
US60/190,076 2000-03-17
US19812300P 2000-04-18 2000-04-18
US60/198,123 2000-04-18
US20551500P 2000-05-19 2000-05-19
US60/205,515 2000-05-19
US20946700P 2000-06-07 2000-06-07
US60/209,467 2000-06-07
US21488600P 2000-06-28 2000-06-28
US60/214,886 2000-06-28
US21513500P 2000-06-30 2000-06-30
US60/215,135 2000-06-30
US21688000P 2000-07-07 2000-07-07
US21664700P 2000-07-07 2000-07-07
US60/216,647 2000-07-07
US60/216,880 2000-07-07
US21749600P 2000-07-11 2000-07-11
US21748700P 2000-07-11 2000-07-11
US60/217,487 2000-07-11
US60/217,496 2000-07-11
US21829000P 2000-07-14 2000-07-14
US60/218,290 2000-07-14
US22096300P 2000-07-26 2000-07-26
US22096400P 2000-07-26 2000-07-26
US60/220,963 2000-07-26
US60/220,964 2000-07-26
US22451900P 2000-08-14 2000-08-14
US22521400P 2000-08-14 2000-08-14
US22521300P 2000-08-14 2000-08-14
US22544700P 2000-08-14 2000-08-14
US22575800P 2000-08-14 2000-08-14
US22526800P 2000-08-14 2000-08-14
US22526600P 2000-08-14 2000-08-14
US22527000P 2000-08-14 2000-08-14
US22575900P 2000-08-14 2000-08-14
US22526700P 2000-08-14 2000-08-14
US22575700P 2000-08-14 2000-08-14
US22451800P 2000-08-14 2000-08-14
US60/225,213 2000-08-14
US60/225,270 2000-08-14
US60/225,758 2000-08-14
US60/225,447 2000-08-14
US60/225,267 2000-08-14
US60/225,759 2000-08-14
US60/225,266 2000-08-14
US60/225,757 2000-08-14
US60/224,519 2000-08-14
US60/225,214 2000-08-14
US60/224,518 2000-08-14
US60/225,268 2000-08-14
US22627900P 2000-08-18 2000-08-18
US60/226,279 2000-08-18
US22668100P 2000-08-22 2000-08-22
US22686800P 2000-08-22 2000-08-22
US22718200P 2000-08-22 2000-08-22
US60/226,868 2000-08-22
US60/226,681 2000-08-22
US60/227,182 2000-08-22
US22700900P 2000-08-23 2000-08-23
US60/227,009 2000-08-23
US22892400P 2000-08-30 2000-08-30
US60/228,924 2000-08-30
US22934300P 2000-09-01 2000-09-01
US22934400P 2000-09-01 2000-09-01
US22928700P 2000-09-01 2000-09-01
US22934500P 2000-09-01 2000-09-01
US60/229,287 2000-09-01
US60/229,344 2000-09-01
US60/229,345 2000-09-01
US60/229,343 2000-09-01
US22950900P 2000-09-05 2000-09-05
US22951300P 2000-09-05 2000-09-05
US60/229,513 2000-09-05
US60/229,509 2000-09-05
US23043800P 2000-09-06 2000-09-06
US23043700P 2000-09-06 2000-09-06
US60/230,438 2000-09-06
US60/230,437 2000-09-06
US23208000P 2000-09-08 2000-09-08
US23208100P 2000-09-08 2000-09-08
US23141300P 2000-09-08 2000-09-08
US23124300P 2000-09-08 2000-09-08
US23141400P 2000-09-08 2000-09-08
US23124200P 2000-09-08 2000-09-08
US23124400P 2000-09-08 2000-09-08
US60/232,080 2000-09-08
US60/231,414 2000-09-08
US60/231,413 2000-09-08
US60/231,242 2000-09-08
US60/231,243 2000-09-08
US60/232,081 2000-09-08
US60/231,244 2000-09-08
US23196800P 2000-09-12 2000-09-12
US60/231,968 2000-09-12
US23306400P 2000-09-14 2000-09-14
US23306500P 2000-09-14 2000-09-14
US23240000P 2000-09-14 2000-09-14
US23240100P 2000-09-14 2000-09-14
US23306300P 2000-09-14 2000-09-14
US23239800P 2000-09-14 2000-09-14
US23239700P 2000-09-14 2000-09-14
US23239900P 2000-09-14 2000-09-14
US60/233,065 2000-09-14
US60/233,063 2000-09-14
US60/232,398 2000-09-14
US60/233,064 2000-09-14
US60/232,399 2000-09-14
US60/232,401 2000-09-14
US60/232,400 2000-09-14
US60/232,397 2000-09-14
US23427400P 2000-09-21 2000-09-21
US23422300P 2000-09-21 2000-09-21
US60/234,223 2000-09-21
US60/234,274 2000-09-21
US23499700P 2000-09-25 2000-09-25
US23499800P 2000-09-25 2000-09-25
US60/234,997 2000-09-25
US60/234,998 2000-09-25
US23548400P 2000-09-26 2000-09-26
US60/235,484 2000-09-26
US23583600P 2000-09-27 2000-09-27
US23583400P 2000-09-27 2000-09-27
US60/235,834 2000-09-27
US60/235,836 2000-09-27
US23636800P 2000-09-29 2000-09-29
US23632700P 2000-09-29 2000-09-29
US23636700P 2000-09-29 2000-09-29
US23636900P 2000-09-29 2000-09-29
US23637000P 2000-09-29 2000-09-29
US60/236,368 2000-09-29
US60/236,370 2000-09-29
US60/236,369 2000-09-29
US60/236,327 2000-09-29
US60/236,367 2000-09-29
US23680200P 2000-10-02 2000-10-02
US23703800P 2000-10-02 2000-10-02
US23703900P 2000-10-02 2000-10-02
US23704000P 2000-10-02 2000-10-02
US23703700P 2000-10-02 2000-10-02
US60/237,037 2000-10-02
US60/237,039 2000-10-02
US60/236,802 2000-10-02
US60/237,038 2000-10-02
US60/237,040 2000-10-02
US23993700P 2000-10-13 2000-10-13
US23993500P 2000-10-13 2000-10-13
US60/239,937 2000-10-13
US60/239,935 2000-10-13
US24178500P 2000-10-20 2000-10-20
US24178600P 2000-10-20 2000-10-20
US24182600P 2000-10-20 2000-10-20
US24180900P 2000-10-20 2000-10-20
US24178700P 2000-10-20 2000-10-20
US24180800P 2000-10-20 2000-10-20
US24122100P 2000-10-20 2000-10-20
US24096000P 2000-10-20 2000-10-20
US60/241,809 2000-10-20
US60/241,785 2000-10-20
US60/241,221 2000-10-20
US60/241,786 2000-10-20
US60/241,826 2000-10-20
US60/241,787 2000-10-20
US60/240,960 2000-10-20
US60/241,808 2000-10-20
US24461700P 2000-11-01 2000-11-01
US60/244,617 2000-11-01
US24661100P 2000-11-08 2000-11-08
US24652400P 2000-11-08 2000-11-08
US24652600P 2000-11-08 2000-11-08
US24660900P 2000-11-08 2000-11-08
US24647400P 2000-11-08 2000-11-08
US24647800P 2000-11-08 2000-11-08
US24652300P 2000-11-08 2000-11-08
US24661000P 2000-11-08 2000-11-08
US24647600P 2000-11-08 2000-11-08
US24653200P 2000-11-08 2000-11-08
US24661300P 2000-11-08 2000-11-08
US60/246,476 2000-11-08
US60/246,526 2000-11-08
US60/246,609 2000-11-08
US60/246,528 2000-11-08
US60/246,532 2000-11-08
US60/246,478 2000-11-08
US60/246,523 2000-11-08
US60/246,475 2000-11-08
US60/246,610 2000-11-08
US60/246,474 2000-11-08
US60/246,527 2000-11-08
US60/246,525 2000-11-08
US60/246,611 2000-11-08
US60/246,613 2000-11-08
US60/246,477 2000-11-08
US60/246,524 2000-11-08
US60/249,217 2000-11-17
US60/249,300 2000-11-17
US60/249,214 2000-11-17
US60/249,215 2000-11-17
US60/249,209 2000-11-17
US60/249,207 2000-11-17
US60/249,244 2000-11-17
US60/249,299 2000-11-17
US60/249,213 2000-11-17
US60/249,211 2000-11-17
US60/249,245 2000-11-17
US60/249,218 2000-11-17
US60/249,208 2000-11-17
US60/249,297 2000-11-17
US60/249,216 2000-11-17
US60/249,264 2000-11-17
US60/249,265 2000-11-17
US60/249,212 2000-11-17
US60/249,210 2000-11-17
US60/250,160 2000-12-01
US60/250,391 2000-12-01
US60/256,719 2000-12-05
US60/251,030 2000-12-05
US60/251,988 2000-12-05
US60/251,479 2000-12-06
US60/251,989 2000-12-08
US60/251,990 2000-12-08
US60/251,856 2000-12-08
US60/251,868 2000-12-08
US60/251,869 2000-12-08
US60/254,097 2000-12-11
US60/259,678 2001-01-05

Publications (3)

Publication Number Publication Date
WO2001055300A2 WO2001055300A2 (en) 2001-08-02
WO2001055300A8 WO2001055300A8 (en) 2001-09-07
WO2001055300A3 true WO2001055300A3 (en) 2002-01-03

Family

ID=27587119

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/001238 WO2001055300A2 (en) 2000-01-31 2001-01-17 Nucleic acids, proteins, and antibodies

Country Status (2)

Country Link
CA (1) CA2394022A1 (en)
WO (1) WO2001055300A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141417B1 (en) 1999-02-25 2006-11-28 Thomas Jefferson University Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene
WO2000050565A2 (en) * 1999-02-25 2000-08-31 Thomas Jefferson University Compositions, kits, and methods relating to the human fez1 gene, a novel tumor suppressor gene
AU6748901A (en) * 2000-05-30 2001-12-11 Bayer Aktiengesellschaft Regulation of human plc delta-1
EP1637601A3 (en) * 2001-02-21 2006-03-29 Curagen Corporation Proteins, polynucleotides encoding them and methods of using the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016178A2 (en) * 1992-02-12 1993-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sequences characteristic of human gene transcription product
WO2000055173A1 (en) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. Human breast and ovarian cancer associated gene sequences and polypeptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016178A2 (en) * 1992-02-12 1993-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sequences characteristic of human gene transcription product
WO2000055173A1 (en) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. Human breast and ovarian cancer associated gene sequences and polypeptides

Also Published As

Publication number Publication date
WO2001055300A8 (en) 2001-09-07
WO2001055300A2 (en) 2001-08-02
CA2394022A1 (en) 2001-08-02

Similar Documents

Publication Publication Date Title
WO2001055303A3 (en) Nucleic acids, proteins, and antibodies
WO2002000677A8 (en) Nucleic acids, proteins, and antibodies
WO2001059063A3 (en) Nucleic acids, proteins, and antibodies
WO2001055317A3 (en) Nucleic acids, proteins, and antibodies
WO2001055300A8 (en) Nucleic acids, proteins, and antibodies
WO2001055313A8 (en) Nucleic acids, proteins, and antibodies
WO2001055329A3 (en) Nucleic acids, proteins, and antibodies
WO2001055305A3 (en) Nucleic acids, proteins, and antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 31/2001 UNDER "PUBLISHED", ADD "WITH SEQUENCE LISTING PART OF DESCRIPTION PUBLISHED SEPARATELY IN ELECTRONIC FORM AND AVAILABLE UPON REQUEST FROM THE INTERNATIONAL BUREAU."

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2394022

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001910325

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001910325

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001910325

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)